The Therapeutic Potential of Rho Kinase Inhibitor Fasudil Derivative FaD-1 in Experimental Autoimmune Encephalomyelitis

Journal of Molecular Neuroscience

Volumn 55, Issue 3, 2015, Pages 725-732

  Zhao, Yong Fei ^a   Zhang, Xiang ^a   Ding, Zhi Bin ^b,c   Yang, Xing Wang ^b,d   Zhang, Hui ^b,c   Yu, Jie Zhong ^b   Li, Yan Hua ^b   Liu, Chun Yun ^b   Zhang, Qing ^a   Zhang, Hong Zhen ^d   Ma, Cun Gen ^b,c,d   Xiao, Bao Guo ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANXI DATONG UNIVERSITY   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

^d SHANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Experimental autoimmune encephalomyelitis; FaD 1; Fasudil derivative; Immunomodulation; Rho kinase inhibitor

Indexed keywords

FAD 1; FASUDIL; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN DERIVATIVE; PROTEIN KINASE INHIBITOR; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMYELINATION; DRUG EFFICACY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOHISTOCHEMISTRY; MONONUCLEAR CELL; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; TH1 CELL; TH17 CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; METABOLISM; PATHOLOGY; SPINAL CORD;

MUS;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERFERON-GAMMA; INTERLEUKINS; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SPINAL CORD; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922269397     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0411-7     Document Type: Article

References (46)

1. Benveniste EN (1997) Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75:165–173
2. Caplan S, Zeliger S, Wang L, Baniyash M (1995) Cell-surface-expressed T-cell antigen-receptor zeta chain is associated with the cytoskeleton. Proc Natl Acad Sci U S A 92:4768–4772
3. Chan CC (2008) Inflammation: beneficial or detrimental after spinal cord injury? Recent Pat CNS Drug Discov 13:189–199
4. Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, Wei X, Chou G, Wang ZT, Mani S (2013) Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr 110:599–608
5. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH (2010) T cells in MS and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162:1–11
6. Fujimoto S, Negishi M, Katoh H (2011) RhoG promotes neural progenitor cell proliferation in mouse cerebral cortex. Mol Biol Cell 20:4941–4950
7. Gensel JC, Nakamura S, Guan Z, van Rooijen N, Ankeny DP, Popovich PG (2009) Macrophages promote axon regeneration with concurrent neurotoxicity. J Neurosci 13:3956–3968
8. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279:509–514
9. Hauser SL, Chan JR, Oksenberg JR (2013) Multiple sclerosis: prospects and promise. Ann Neurol 74:317–327
10. Hirose M, Ishizaki T, Watanabe N, Uehata M, Kranenburg O, Moolenaar WH, Matsumura F, Maekawa M, Bito H, Narumiya S (1998) Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol 141:1625–1636
11. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, Garefalaki A, Potocnik AJ, Stockinger B (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12:255–263
12. Hou SW, Liu CY, Li YH, Yu JZ, Feng L, Liu YT, Guo MF, Xie Y, Meng J, Zhang HF, Xiao BG, Ma CG (2012) Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. CNS Neurosci Ther 18:909–917
13. Huang XN, Fu J, Wang WZ (2011) The effects of fasudil on the permeability of the rat blood–brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis. J Neuroimmunol 239:61–67
14. Kattah MG, Wong MT, Yocum MD, Utz PJ (2008) Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthritis Rheum 58:1619–1629
15. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, Duquette P, Prat A (2009) Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 66:390–402
16. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, Zanardo RC, Bonder C, James WG, Robbins SM, Kubes P (2004) TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol 173:7070–7077
17. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG (2009) Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 11:13435–13444
18. Li Q, Huang XJ, He W, Ding J, Jia JT, Fu G, Wang HX, Guo LJ (2009) Neuroprotective potential of fasudil mesylate in brain ischemia-reperfusion injury of rats. Cell Mol Neurobiol 29:169–180
19. Liu CY, Li YH, Yu JZ, Feng L, Hou SW, Liu Y, Guo M, Xie Y, Meng J, Zhang H, Xiao B, Ma C (2013) Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with Fasudil. PLoS One 8:e54841
20. Mahurkar S, Suppiah V, O’Doherty C (2014) Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Autoimmun Rev 13:178–186
21. Minagar A (2013) Current and future therapies for multiple sclerosis. Sci 249101
22. Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJ, Ffrench-Constant C (2013) M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 16:1211–1218
23. Mueller BK, Mack H, Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387–398
24. Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 13:723–737
25. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392:189–193
26. Niederöst B, Oertle T, Fritsche J, McKinney RA, Bandtlow CE (2002) Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J Neurosci 22:10368–10376
27. Oh J, Calabresi PA (2013) Emerging injectable therapies for multiple sclerosis. Lancet Neurol 12:1115–1126
28. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19:1264–72
29. Reynolds JM, Martinez GJ, Chung Y, Dong C (2012) Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci U S A 109:13064–13069
30. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL (2013) Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson’s disease. Neurobiol Dis 58:209–219
31. Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ (2008) Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol 181:5120–5127
32. Rozdzial MM, Pleiman CM, Cambier JC, Finkel TH (1998) pp56Lck mediates TCR zeta-chain binding to the microfilament cytoskeleton. J Immunol 161:5491–5499
33. Song Y, Chen X, Wang LY, Gao W, Zhu MJ (2013) Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther 19:603–610
34. Stadelmann CC, Wegner C, Bruck W (2011) Inflammation, demyelination, and degeneration—recent insights from MS pathology. Biochim Biophys Acta 1812:275–282
35. Sun X, Minohara M, Kikuchi H, Ishizu T, Tanaka M, Piao H, Osoegawa M, Ohyagi Y, Shimokawa H, Kira J (2006) The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 180:126–134
36. Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H (2013) Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol 170:341–351
37. Tharaux PL, Bukoski RC, Rocha PN, Crowley SD, Ruiz P, Nataraj C, Howell DN, Kaibuchi K, Spurney RF, Coffman TM (2003) Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells. J Immunol 171:96–105
38. Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, Bähr M, Weishaupt JH, Lingor P (2012) Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson’s disease. Brain 135:3355–3370
39. van de Veerdonk FL, Teirlinck AC, Kleinnijenhuis J, Kullberg BJ, van Crevel R, van der Meer JW, Joosten LA, Netea MG (2010) Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. J Leukoc Biol 88:227–232
40. van der Valk P, De Groot CJ (2000) Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol 26:2–10
41. Visser L, Jan de Heer H, Boven LA, van Riel D, van Meurs M, Melief MJ, Zahringer U, van Strijp J, Lambrecht BN, Nieuwenhuis EE, Laman JD (2005) Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J Immunol 174:808–816
42. Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C (2004) Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127:1370–1378
43. Yu JZ, Ding J, Ma CG, Sun CH, Sun YF, Lu CZ, Xiao BG (2010) Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J Neurosci Res 88:1664–1672
44. Zekki H, Feinstein DL, Rivest S (2002) The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol 12:308–319
45. Zhang XM, Lund H, Mia S, Parsa R, Harris RA (2014) Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA/1 mice. Glia 62:804–17
46. Zhou Y, Ye L, Wan Q, Zhou L, Wang X, Li J, Hu S, Zhou D, Ho W (2009) Activation of Toll-like receptors inhibits herpes simplex virus-1 infection of human neuronal cells. J Neurosci Res 87:2916–2925